The head and shoulders pattern successfully played out, with 
NOVO_B reaching my full target at 670.
Check out my original post:
The stock experienced a significant drop, falling as much as 27% on the Friday before Christmas. This was triggered by test results for their obesity drug, CagriSema, which showed patient weight loss of 22.7% - below the anticipated 25%.
I believe this reaction is an overcorrection and have taken advantage of this rare opportunity to purchaseNOVO_B, first at 680 and again at 600. I now plan to hold patiently, expecting Novo Nordisk to reach new all-time highs in the coming years.
NOVO_B reaching my full target at 670.Check out my original post:
The stock experienced a significant drop, falling as much as 27% on the Friday before Christmas. This was triggered by test results for their obesity drug, CagriSema, which showed patient weight loss of 22.7% - below the anticipated 25%.
I believe this reaction is an overcorrection and have taken advantage of this rare opportunity to purchase
NOVO_B, first at 680 and again at 600. I now plan to hold patiently, expecting Novo Nordisk to reach new all-time highs in the coming years.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。